Neurocognitive Effects of Opiate Agonist Treatment (NEO)
Sponsor: Albert Einstein College of Medicine
Listed as NCT01733693, this PHASE4 trial focuses on HIV and HIV Infections and remains completed. Sponsored by Albert Einstein College of Medicine, it has been updated 11 times since 2013, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE4
-
May 2021 — Mar 2022 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE4
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Einstein College of Medicine
- Fordham University
- Montefiore Medical Center
- National Institute on Drug Abuse (NIDA)
For direct contact, visit the study record on ClinicalTrials.gov .